Related Experiment Videos
Strontium-89 chloride for pain palliation in prostatic skeletal malignancy
A H Laing1, D M Ackery, R J Bayly
1Department of Radiotherapy, Churchill Hospital, Oxford, UK.
The British Journal of Radiology
|September 1, 1991
Summary
Strontium-89 effectively relieved bone pain in advanced prostate cancer patients. Most patients experienced significant pain reduction, with some becoming pain-free, offering a new therapeutic option.
Area of Science:
- Oncology
- Radiopharmaceuticals
- Pain Management
Background:
- Prostate carcinoma frequently metastasizes to bone, causing significant pain.
- Conventional therapies often fail to provide adequate relief for bone pain in advanced prostate cancer.
Purpose of the Study:
- To evaluate the efficacy and safety of strontium-89 in managing bone pain associated with prostate cancer.
- To determine the optimal dosage and treatment interval for strontium-89 therapy.
Main Methods:
- Multi-center study involving 83 patients with prostate cancer and bone pain.
- Administration of strontium-89 at a dose of at least 1.5 MBq/kg.
- Assessment of pain relief and toxicity at 3 months post-treatment.
Main Results:
- 75% of patients experienced pain relief, and 22% became pain-free within 3 months.
- Symptomatic improvement occurred within 6 weeks and lasted an average of 6 months.
- Recommended dose is 150 MBq; toxicity was low with adequate platelet counts.
Conclusions:
- Strontium-89 is an effective palliative treatment for bone pain in prostate cancer patients.
- The recommended dose is 150 MBq with low toxicity and manageable side effects.
- Outpatient administration is feasible without special radiological precautions.